Profile data is unavailable for this security.
About the company
Thermo Fisher Scientific Inc. is engaged in helping life sciences research, increasing laboratory productivity, and improving patient health through diagnostics and the development and manufacture of life-changing therapies. The Company's Life Sciences Solutions segment provides a portfolio of reagents, instruments and consumables used in biological and medical research, discovery and production of new drugs and vaccines as well as diagnosis of infection and disease. Analytical Instruments segment provides instruments and the supporting consumables, software and services that are used for a range of applications in the laboratory and in the field. Specialty Diagnostics segment offers a range of diagnostic test kits, reagents, culture media, instruments and associated products to serve customers in healthcare, clinical, pharmaceutical, industrial, and food safety laboratories. The Laboratory Products and Biopharma Services segment offers virtually everything needed for the laboratory.
- Revenue in USD (TTM)42.86bn
- Net income in USD6.00bn
- Incorporated1960
- Employees122.00k
- LocationThermo Fisher Scientific Inc168 Third AvenueWALTHAM 02451United StatesUSA
- Phone+1 (781) 622-1000
- Fax+1 (781) 622-1207
- Websitehttps://www.thermofisher.com/
Mergers & acquisitions
Acquired company | TMO:NYQ since announced | Transaction value |
---|---|---|
CorEvitas LLC | 11.64% | 912.50m |
MarqMetrix Inc | 10.20% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DexCom Inc | 3.62bn | 541.50m | 53.77bn | 9.60k | 108.80 | 25.99 | 73.91 | 14.84 | 1.28 | 1.28 | 8.55 | 5.37 | 0.6215 | 3.04 | 4.29 | 377,322.90 | 9.29 | 8.30 | 13.11 | 10.50 | 63.65 | 65.90 | 14.95 | 14.14 | 2.48 | -- | 0.5465 | 0.00 | 24.49 | 28.56 | 58.70 | -- | 28.66 | -- |
Edwards Lifesciences Corp | 6.00bn | 1.40bn | 57.21bn | 19.80k | 41.34 | 8.60 | 37.05 | 9.53 | 2.30 | 2.30 | 9.85 | 11.06 | 0.6802 | 1.35 | 8.47 | 303,272.70 | 15.85 | 16.63 | 18.21 | 19.12 | 77.02 | 76.71 | 23.30 | 24.84 | 2.40 | -- | 0.0816 | 0.00 | 11.56 | 10.03 | -7.85 | 13.70 | 1.96 | -- |
Becton Dickinson and Co | 19.49bn | 1.27bn | 71.22bn | 73.00k | 56.26 | 2.81 | 20.08 | 3.65 | 4.38 | 4.23 | 67.25 | 87.68 | 0.3699 | 3.31 | 8.57 | 267,013.70 | 2.47 | 2.37 | 2.89 | 2.70 | 41.37 | 45.78 | 6.68 | 6.95 | 0.6435 | 6.45 | 0.3887 | 81.23 | 2.66 | 3.92 | -4.85 | 12.97 | -0.4737 | 3.94 |
Boston Scientific Corporation | 14.24bn | 1.57bn | 100.86bn | 48.00k | 64.07 | 5.22 | 36.47 | 7.08 | 1.07 | 1.07 | 9.73 | 13.16 | 0.4213 | 1.99 | 6.78 | 296,666.70 | 4.71 | 2.50 | 5.43 | 2.91 | 69.65 | 68.84 | 11.18 | 6.47 | 0.8170 | 5.16 | 0.3179 | 0.00 | 12.29 | 7.71 | 144.55 | -0.4276 | 7.82 | -- |
Medtronic PLC | 32.32bn | 4.20bn | 115.41bn | 95.00k | 27.56 | 2.23 | 16.71 | 3.57 | 3.15 | 3.15 | 24.27 | 38.95 | 0.3495 | 2.00 | 5.45 | 340,210.50 | 4.58 | 4.78 | 5.28 | 5.37 | 65.73 | 67.68 | 13.10 | 14.28 | 1.71 | 30.78 | 0.3263 | 72.49 | -1.45 | 0.8366 | -25.42 | -6.95 | 6.44 | 8.13 |
Stryker Corp | 20.50bn | 3.17bn | 136.40bn | 52.00k | 43.49 | 7.33 | 32.53 | 6.65 | 8.25 | 8.25 | 53.42 | 48.92 | 0.5338 | 1.67 | 5.59 | 394,192.30 | 8.24 | 6.60 | 10.12 | 7.84 | 63.90 | 63.99 | 15.44 | 13.13 | 0.9689 | -- | 0.4114 | 43.70 | 11.11 | 8.55 | 34.22 | 9.68 | 0.1047 | 10.16 |
Intuitive Surgical, Inc. | 7.12bn | 1.80bn | 141.81bn | 13.68k | 79.57 | 10.59 | 62.42 | 19.91 | 5.03 | 5.03 | 19.93 | 37.77 | 0.5014 | 2.27 | 6.88 | 520,919.90 | 12.79 | 12.42 | 14.44 | 13.83 | 66.39 | 67.60 | 25.51 | 26.31 | 4.02 | -- | 0.00 | 0.00 | 14.49 | 13.85 | 35.98 | 9.77 | 41.53 | -- |
Abbott Laboratories | 40.11bn | 5.72bn | 196.91bn | 114.00k | 34.68 | 5.10 | 21.96 | 4.91 | 3.27 | 3.27 | 22.93 | 22.26 | 0.5433 | 2.81 | 6.28 | 351,833.30 | 7.75 | 7.72 | 9.71 | 9.39 | 55.32 | 56.73 | 14.27 | 14.39 | 1.16 | 22.94 | 0.2743 | 54.95 | -8.12 | 5.58 | -17.45 | 18.36 | 9.57 | 12.74 |
Thermo Fisher Scientific Inc | 42.86bn | 6.00bn | 220.92bn | 122.00k | 37.50 | 4.79 | 23.45 | 5.15 | 15.45 | 15.45 | 110.46 | 120.87 | 0.4376 | 4.80 | 4.49 | 351,286.90 | 6.14 | 7.79 | 7.31 | 9.11 | 39.90 | 44.94 | 14.03 | 16.76 | 1.39 | 16.34 | 0.4271 | 6.75 | -4.58 | 11.96 | -13.74 | 14.43 | 14.30 | 15.39 |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 31 Dec 2023 | 31.33m | 8.22% |
BlackRock Fund Advisorsas of 31 Dec 2023 | 17.17m | 4.50% |
SSgA Funds Management, Inc.as of 31 Dec 2023 | 16.48m | 4.32% |
Capital Research & Management Co. (World Investors)as of 31 Dec 2023 | 12.26m | 3.22% |
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 2023 | 9.35m | 2.45% |
Capital Research & Management Co. (Global Investors)as of 31 Dec 2023 | 7.99m | 2.10% |
Geode Capital Management LLCas of 31 Dec 2023 | 7.29m | 1.91% |
Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 6.46m | 1.70% |
Norges Bank Investment Managementas of 31 Dec 2023 | 5.48m | 1.44% |
Massachusetts Financial Services Co.as of 31 Dec 2023 | 4.18m | 1.10% |